Article
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check
21 May 2008
Abstract excerpt
Targeted therapy with the Abl kinase inhibitor imatinib has markedly improved the outlook for patients with chronic myeloid leukemia (CML). Breakpoint cluster region (Bcr)-Abl signaling is reactivated at the time of resistance, predominantly due to mutations in the kinase domain of Bcr-Abl that interfere with drug binding. This discovery prompted the development of new Abl kinase inhibitors, among which nilotinib...
Topics
Join the communities discussing this publication.